Literature DB >> 12695152

Applying low disease activity criteria using the DAS28 to assess stability in patients with rheumatoid arthritis.

H J M Vrijhoef1, J P M Diederiks, C Spreeuwenberg, Sj Van der Linden.   

Abstract

OBJECTIVES: To examine whether low disease activity criteria using the disease activity score (DAS28) can be applied to identify a reasonably large number of patients with stable low disease activity of rheumatoid arthritis (RA) over a six month period, with the ultimate intention of including these patients in a substitution based, shared care model. Additionally, to assess the reliability of the DAS28 for selecting patients with stable disease from an outpatient population.
METHODS: Patients regularly seen at the rheumatology outpatient department of the university hospital Maastricht, were invited for assessment of the stability of their RA. The shared care model was intended to provide care to patients with stable, low disease activity of RA by nurse specialists. For this, patients underwent assessments using the DAS28 criteria at entry and three and six months later. Test-retest reliability was assessed for composing measures as well as for the DAS28.
RESULTS: Of the 97 outpatients included, one third (31 patients) did not complete the study. Patients with missing data were older and assessed their disease activity as greater than patients with complete data. Applying the low disease activity criteria to assess stability over a period of six months (DAS28(T0)</=3.2 and DAS28(T6)-DAS28(T0)</=1.2) resulted in identification of 22/56 (39%) patients with stable, low disease activity of RA. A good similarity score (intraclass correlation coefficient=0.82) for the DAS28 was found.
CONCLUSIONS: The low disease activity criteria using the DAS28 can be used to select patients with stable, low disease activity of RA from a rheumatic outpatient population.

Entities:  

Mesh:

Year:  2003        PMID: 12695152      PMCID: PMC1754526          DOI: 10.1136/ard.62.5.419

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  12 in total

Review 1.  Skill mix between nurses and doctors working in primary care-delegation or allocation: a review of the literature.

Authors:  A Richards; J Carley; S Jenkins-Clarke; D A Richards
Journal:  Int J Nurs Stud       Date:  2000-06       Impact factor: 5.837

2.  Advances in managing chronic disease. Research, performance measurement, and quality improvement are key.

Authors:  R M Davis; E G Wagner; T Groves
Journal:  BMJ       Date:  2000-02-26

3.  Adoption of disease management model for diabetes in region of Maastricht.

Authors:  H J Vrijhoef; C Spreeuwenberg; I M Eijkelberg; B H Wolffenbuttel; G G van Merode
Journal:  BMJ       Date:  2001-10-27

4.  Estimating the reliability of continuous measures with Cronbach's alpha or the intraclass correlation coefficient: toward the integration of two traditions.

Authors:  G Bravo; L Potvin
Journal:  J Clin Epidemiol       Date:  1991       Impact factor: 6.437

5.  Teams and seams: skill mix in primary care.

Authors:  S Jenkins-Clarke; R Carr-Hill; P Dixon
Journal:  J Adv Nurs       Date:  1998-11       Impact factor: 3.187

Review 6.  Assessing the activity of rheumatoid arthritis.

Authors:  M Boers; P L van Riel; D T Felson; P Tugwell
Journal:  Baillieres Clin Rheumatol       Date:  1995-05

7.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

8.  Validity and reliability of joint indices. A longitudinal study in patients with recent onset rheumatoid arthritis.

Authors:  M L Prevoo; P L van Riel; M A van 't Hof; M H van Rijswijk; M A van Leeuwen; H H Kuper; L B van de Putte
Journal:  Br J Rheumatol       Date:  1993-07

9.  Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria.

Authors:  A M van Gestel; M L Prevoo; M A van 't Hof; M H van Rijswijk; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1996-01

10.  American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.

Authors:  D T Felson; J J Anderson; M Boers; C Bombardier; D Furst; C Goldsmith; L M Katz; R Lightfoot; H Paulus; V Strand
Journal:  Arthritis Rheum       Date:  1995-06
View more
  8 in total

1.  Factors influencing quality of life (QOL) for Korean patients with rheumatoid arthritis (RA).

Authors:  Soo-Kyung Cho; Dam Kim; Jae-Bum Jun; Sang-Cheol Bae; Yoon-Kyoung Sung
Journal:  Rheumatol Int       Date:  2012-01-05       Impact factor: 2.631

2.  Retrospective clinical study of the efficacy of lower-dose methotrexate and infliximab therapy in patients with rheumatoid arthritis.

Authors:  Hiroki Wakabayashi; Akihiro Sudo; Masahiro Hasegawa; Hiroshi Oka; Atsumasa Uchida; Kusuki Nishioka
Journal:  Clin Rheumatol       Date:  2010-03-04       Impact factor: 2.980

3.  Short-term efficacy and safety of leflunomide in the treatment of active rheumatoid arthritis in everyday clinical use : open-label, prospective study.

Authors:  Minh Nguyen; Marmar Kabir; Philippe Ravaud
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

4.  Distinguishing fibromyalgia from rheumatoid arthritis and systemic lupus in clinical questionnaires: an analysis of the revised Fibromyalgia Impact Questionnaire (FIQR) and its variant, the Symptom Impact Questionnaire (SIQR), along with pain locations.

Authors:  Ronald Friend; Robert M Bennett
Journal:  Arthritis Res Ther       Date:  2011-04-08       Impact factor: 5.156

Review 5.  Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis.

Authors:  Joseph R Lutt
Journal:  Open Access Rheumatol       Date:  2009-05-08

6.  The efficacy and safety of the herbal medicine geonchildan for patients with active rheumatoid arthritis: study protocol for a randomized, double-blind, placebo-controlled, parallel pilot trial.

Authors:  Seunghoon Lee; Yeeun Cho; Jihye Kim; Jung Won Kang; Ga Young Yoon; Jun-Hwan Lee; So-Young Jung; Ojin Kwon; Kyung-Min Shin; Jae-Dong Lee
Journal:  Trials       Date:  2018-09-03       Impact factor: 2.279

7.  The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial.

Authors:  M Schiff; C Pritchard; J E Huffstutter; V Rodriguez-Valverde; P Durez; X Zhou; T Li; K Bahrt; S Kelly; M Le Bars; M C Genovese
Journal:  Ann Rheum Dis       Date:  2008-12-15       Impact factor: 19.103

8.  Comparison of remission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patient global health is a confounder.

Authors:  Emese Balogh; Joao Madruga Dias; Carl Orr; Ronan Mullan; Len Harty; Oliver FitzGerald; Phil Gallagher; Miriam Molloy; Eileen O'Flynn; Alexia Kelly; Patricia Minnock; Madeline O'Neill; Louise Moore; Mairead Murray; Ursula Fearon; Douglas J Veale
Journal:  Arthritis Res Ther       Date:  2013-12-24       Impact factor: 5.156

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.